2022年第二版《NCCN肺癌筛查临床实践指南》解读  

Interpretation of updated NCCN clinical practice guidelines for lung cancer screening(version 2.2022)

作　　者：斯浩杰 徐龙 王放 苏杭 佘云浪 戴晨阳 胡学飞[1] 赵德平[1] 朱余明[1] 张鹏[1] 姜格宁[1] 陈昶[1] SI Haojie;XU Long;WANG Fang;SU Hang;SHE Yunlang;DAI Chenyang;HU Xuefei;ZHAO Deping;ZHU Yuming;ZHANG Peng;JIANG Gening;CHEN Chang(Department of Thoracic Surgery,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai,200433,P.R.China)

机构地区：[1]同济大学附属上海市肺科医院胸外科,上海200433

出　　处：《中国胸心血管外科临床杂志》2022年第11期1407-1413,共7页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：国家自然科学基金项目(91959126);上海申康医院发展中心重大疾病多中心临床研究项目(SHDC2020CR1021B);上海申康医院发展中心促进临床专科能力提升项目(SHDC22021310-A)。

摘　　要：肺癌是我国发病率和死亡率最高的恶性肿瘤,肺癌早筛为改善肺癌预后的重要措施。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)于2022年7月更新发布了第二版《NCCN肺癌筛查临床实践指南》。该版指南基于高级别循证医学证据和最新的研究进展制定肺癌筛查标准,其更新受到了全球临床医师的广泛关注。本文将对新版指南内容进行逐一解读,并与中国肺癌筛查指南进行比较,以期为我国现阶段肺癌筛查工作提供参考。Lung cancer is the most common cancer and the leading cause of cancer-related death in China.Early screening of lung cancer proves to be effective in improving its prognosis.The National Comprehensive Cancer Network(NCCN)has updated and released version 2,2022 NCCN clinical practice guidelines for lung cancer screening in July,2022.Based on high-quality clinical evidence and the latest research progress,the guidelines have developed and updated criteria for lung cancer screening which have been widely recognized by clinicians around the world.Compared with Chinese lung cancer screening guidelines,this article will interpret the updated content of the brand new 2022 NCCN screening guidelines,providing some reference for the current lung cancer screening practice in our country.

关 键 词：肺癌筛查 NCCN指南 指南解读 

分 类 号：R734.2[医药卫生—肿瘤]